| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 20, 2024 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
S-1 - Scorpius Holdings, Inc. (0001476963) (Filer)
4 - Scorpius Holdings, Inc. (0001476963) (Issuer)
DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo
DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu
DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX) ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development. She brings more than 25 years of experience in biopharma business development and management. Prior to joining Scorpius, Ms. Udoff-McDonald spent 17 years at BioReliance Corporation, part of MilliporeSigma. She was most recently Head of Commercial, North America, East with interim oversight of half of the European market. Her role included commercial oversight of biologics, vaccines, cell and gene therapies, ADCs, and
SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)
SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)
SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)
DURHAM, N.C., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that the Company's planned 1-for-20 reverse stock split (the "Reverse Stock Split") of its common stock (the "Common Stock") that was announced yesterday, will not be effectuated. Scorpius Holdings, Inc. Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharm
DURHAM, N.C., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"), to increase the selling price of the Company's Common Stock in order to maintain compliance with the requirements and policies of the NYSE American. The Reverse Stock Split will take legal effect at 12:01 A.M. Eastern Time on January 21, 2025, and the Company's Common Stock will open for trading on the NYSE American on January 21,
DURHAM, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced the launch of Scorpius Ventures, a new business unit designed to support emerging biotech companies with a flexible American onshoring model. By combining service fees with an equity stake, Scorpius Ventures lowers financial barriers for its partners to onshore production of their biologics, creating a mutually beneficial pathway to accelerate biotech advancements. Scorpius Ventures' hybrid model offers capital-efficient access to its cGMP manufacturing services through in-kin